Evidence map›Paper›PMID 39046554›Full record

ArticleWorld journal of urology2024

Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens.

Leo Jurascheck Bickley, Yu-Hsuen Yang, Francesca Jackson-Spence, Charlotte Toms, Christopher Sng, Lucy Flanders, Axel Bex, Thomas Powles, Bernadett Szabados

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Perioperative therapies for metastatic renal cell carcinoma.Journal of cancer metastasis and treatment · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Leo Jurascheck BickleyBarts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, UK. leo.jurascheck1@nhs.net.ORCID http://orcid.org/0009-0004-4221-4434
Yu-Hsuen YangBarts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, UK.
Francesca Jackson-SpenceBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Charlotte TomsBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Christopher SngBarts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, UK.
Lucy FlandersBarts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, UK.
Axel BexDepartment of Urology, The Royal Free London NHS Foundation Trust, London, UK.
Thomas PowlesBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Bernadett SzabadosBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate responses in the primary tumour to different systemic treatment regimens in patients with metastatic renal cell carcinoma (mRCC).

methodsA single-centre retrospective analysis of treatment-naive mRCC patients without prior nephrectomy receiving VEGF tyrosine kinase inhibitors (VEGF only), immune checkpoint inhibitors (IO only), or combinations thereof (IO + VEGF). The primary outcome was the rate of partial response in the primary tumour (primary tumour PR, ≥ 30% diameter reduction). Secondary outcomes were time to best primary tumour diameter change, overall survival (OS) and progression-free survival (PFS) by Kaplan-Meier analysis. Predictors of survival outcomes were explored by Cox proportional hazards regression analysis.

resultsThe rate of primary tumour PR was 14% for VEGF only (4/28 patients), 22% for IO only (5/23) and 50% for IO + VEGF (7/14), with median best primary tumour diameter change of - 8.0%, + 5.1%, and - 31.1% respectively, and median time to best primary tumour diameter change of 3.2, 3.0 and 6.9 months respectively. Median OS was significantly greater with IO + VEGF compared to VEGF only (HR 0.45, p = 0.04) and non-significantly greater compared to IO only (HR 0.46, p = 0.06). In multivariable analysis, primary tumour PR was the only response variable significantly associated with both OS (adjusted HR 0.32, p = 0.01) and PFS (adjusted HR 0.29, p < 0.01).

conclusionmRCC patients without prior nephrectomy receiving first-line IO + VEGF regimens showed the greatest primary tumour responses, suggesting further prospective evaluation of this combination in the neoadjuvant and deferred cytoreductive nephrectomy settings.

Indexed as

Angiogenesis InhibitorsCarcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateTreatment OutcomeAngiogenesis InhibitorsImmune Checkpoint InhibitorsAnti-angiogenic drugsImmune checkpoint blockadeNeoadjuvant systemic treatmentsRenal cell carcinomaRetrospective studies

Identifiers

PMID39046554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.